Close Menu

NEW YORK ─ Harvard University spinout Torus Biosystems is planning its entry into the market for syndromic multiplex testing, leveraging a platform that combines convection PCR, nanoarrays, and proprietary probes to enable quantitative detection of a broad range of DNA and RNA biomarkers.

Torus is combining the technologies to develop diagnostic testing products for use near patients that would provide results directly from a sample within 30 minutes, its President and CEO Shawn Marcell said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.